Biotech entity
Every one of those 1 sits in a single category, clinical-trial. Ahmed M. Hamdy is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6.4 for that window.
Last mentioned: Mar 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. Ahmed M. Hamdy is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Their average consequence score of 5 runs below the beat's 6.4 for that window. They are better corroborated than the beat average, carrying 4 original sources each against 2.8 for the same window. We currently track 1 Biotech story that mention James E. Dentzer, all published on March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering James E. Dentzer. Shared-story counts are live from our verified record — not editorial picks.
ASH Annual Meeting
Targeted presentation of initial proof-of-concept data for TakeAim CLL study.
Q4 Earnings Report
Reported $19.4M net income and updated clinical guidance for emavusertib.
PIPE Financing
Secured $20.2 million in initial proceeds with milestone-linked upside.
Erivedge Wind-down
Final Erivedge royalties received before the transition to Oberland.
Curis has transitioned to a pure-play oncology developer, leveraging a $27.2 million gain from the sale of Erivedge royalties to fund its emavusertib clinical programs. With a cash runway extended into 2027, the company is prioritizing its registrational study in lymphoma while reporting high MRD conversion rates in its AML triplet therapy.
James E. Dentzer is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
